<DOC>
	<DOCNO>NCT00100334</DOCNO>
	<brief_summary>This single-center , double-blind , inpatient study follow outpatient , placebo-controlled , multiple-IV injection evaluation safety tolerability PPI-1019 subject mild-moderate Alzheimer ’ disease ( AD ) . The primary objective study assess safety multiple IV injection PPI-1019 subject mild-moderate Alzheimer ’ disease .</brief_summary>
	<brief_title>Safety Study PPI-1019 Subjects With Mild-Moderate Alzheimer ’ Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Subject ability understand requirement study , provide write informed consent , abide requirement study . In addition , member subject ’ family legally authorize representative must consent subject ’ participation study . Subject caregiver willing assist subject ’ involvement study . Subject male female age 50 80 body mass index ( BMI ) 31 . Females must postmenopausal least 1 year surgically sterilize . Subject must cognitive deficit present least 1 year meet DSM –IV criterion Alzheimer ’ disease meet National Institute Neurological Communicative Disorders Stroke/Alzheimer ’ Disease Related Disorders Association ( NINCDS/ADRDA ) criterion presence probable Alzheimer ’ disease . Subject ’ severity Alzheimer ’ disease must mildmoderate , document Mini Mental State Exam ( MMSE ) score 1226 . Subject computerized tomography ( CT ) scan magnetic resonance imaging ( MRI ) within prior 12 month compatible diagnosis probable AD . If subject treat Alzheimer ’ disease , must single cholinesterase inhibitor ( donepezil , rivastigmine , galantamine ) , without memantine , dose stable least 3 month prior dose . Subject performance status ≤ 3 item 1 5 ≤ 2 item 6 Degree Disability Section “ Rapid Disability Scale2 ” Subject agree donate blood blood product participate study least 60 day discontinue study . Subject participate clinical trial another investigational drug device , take experimental drug within 30 day prior admission Phase 1 unit . ( Subjects previously enrol 10190301 may enrol 10190401 , washout period 45 day . ) Subject history compatible vascular dementia evidence score 5 great modify Hachinski Ischemia Scale . Subject evidence clinically significant unstable cardiovascular , renal , hepatic , gastrointestinal , neurological , metabolic disease within past 6 month ( determined medical history , ECG result , chest xray , physical examination ) . Subject performance status &gt; 3 item 1 5 &gt; 2 item 6 Degree Disability Section “ Rapid Disability Scale2. ” Subject diabetes require oral antidiabetic therapy insulin . Subject systolic blood pressure ( sit ) great 160 mmHg , diastolic ( sit ) great 95 mmHg , decrease systolic blood pressure 30 mmHg upon stand 2 minute sit supine position , pulse ( sit supine ) less 50 great 85 . Subject visual , hearing , communication disability impair his/her ability participate study . Subject treat anticholinergic and/or clinically relevant cytochrome P450 3A4 inducers/inhibitors . The use concomitant medication stable medical condition acceptable provide drug dosage stable least 4 week prior dose . Subject currently take herbal supplement interfere drug metabolism , e.g . St. John ’ wort , ginkgo biloba . Subject test positive drug abuse ( amphetamine , barbiturate , cocaine , phencyclidine , cannabinoids ) screen Day 1 Subject current past medical history alcohol abuse . Subject elevation ( &gt; 1.2 x ULN ) screen Day 1 ALT , AST , bilirubin , creatinine , blood urea nitrogen , alkaline phosphatase . Subject screen Day 1 laboratory value outside normal range deem clinically significant investigator .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>